TRV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Travelers Companies Inc (TRV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown solid financial performance in Q4 2025, the technical indicators and options data suggest a neutral to bearish sentiment in the short term. Additionally, insider and hedge fund selling, combined with a lack of recent congress trading data, further weakens the case for immediate investment.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 62.174, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near a key pivot level of 293.363, with resistance at 302.164 and support at 284.561. The stock trend analysis predicts a 90% chance of a -4.69% decline in the next week and -5.73% in the next month, indicating potential near-term weakness.
Strong Q4 2025 financial performance: Revenue increased by 3.51% YoY, Net Income by 19.89% YoY, and EPS by 23.44% YoY.
Analysts have raised price targets recently, with some maintaining positive ratings (e.g., Cantor Fitzgerald, Argus, and Keefe Bruyette).
Insider and hedge fund selling has significantly increased, with insider selling up 421.37% and hedge fund selling up 1401.31%.
Options data indicates bearish sentiment.
Stock trend analysis predicts short-term declines.
Downgrades from Goldman Sachs and Barclays citing softening P&C market and competitive pressures.
In Q4 2025, Travelers reported strong financial growth: Revenue increased to $12.43 billion (+3.51% YoY), Net Income rose to $2.48 billion (+19.89% YoY), and EPS grew to $11.06 (+23.44% YoY). These results were driven by lower catastrophe losses, higher net investment income, and increased capital returns.
Analyst ratings are mixed but lean slightly positive. Recent upgrades include Cantor Fitzgerald raising the price target to $319 with an Overweight rating and Argus raising the target to $295 with a Buy rating. However, some firms, like Goldman Sachs and Barclays, have downgraded the stock, citing challenges in the P&C insurance sector and competitive pressures.
